Parabilis Medicines Inc.
PBLS | NASDAQ
$28.32
-$0.38 (-1.32%)
At close: Oct 30, 2026, 4:00 PM ET
$28.16
-$0.16 (-0.56%)
Pre-market:
Nov 2, 2026, 9:16 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 |
|---|---|---|
Cash & Equivalents | 27.71M | 47.28M |
Short-Term Investments | n/a | 40.69M |
Long-Term Investments | n/a | n/a |
Other Long-Term Assets | 5.39M | 4.12M |
Receivables | n/a | 360K |
Inventory | n/a | n/a |
Other Current Assets | 1.65M | 3.87M |
Total Current Assets | 29.36M | 92.21M |
Property-Plant & Equipment | 46.08M | 52.93M |
Goodwill & Intangibles | n/a | n/a |
Total Long-Term Assets | 51.46M | 57.05M |
Total Assets | 80.82M | 149.25M |
Account Payables | 17.27M | 9.51M |
Deferred Revenue | n/a | n/a |
Short-Term Debt | 13.08M | 2.5M |
Other Current Liabilities | 10.3M | 6.97M |
Total Current Liabilities | 56.79M | 32.41M |
Long-Term Debt | n/a | 12.79M |
Other Long-Term Liabilities | 2.74M | 3.58M |
Total Long-Term Liabilities | 40.55M | 60.4M |
Total Liabilities | 97.34M | 92.81M |
Total Debt | 58.7M | 66.2M |
Book Value | -16.52M | 56.44M |
Book Value Per Share | -8.17 | 29.18 |
Common Stock | n/a | n/a |
Retained Earnings | -541.5M | -395.62M |
Comprehensive Income | n/a | 21K |
Shareholders Equity | -16.52M | 56.44M |
Total Investments | n/a | 40.69M |
Add to Watchlist
Select watchlists to add or remove PBLS